We are Genomics England and our vision is to create a world where everyone benefits from genomic hea
Digital consent models, language barriers, and cultural differences are just a few factors that can
For Sickle Cell Awareness Month, our sickle cell Patient Voice Group discuss their lived experiences
In this episode of Behind the Genes, we explore the challenges diverse communities face in accessing
Pharmacogenomics plays a critical role in personalised medicine, as some adverse drug reactions are
In this episode, we delve into the impact of the new groundbreaking research uncovering the RNU4-2 g
Genomics has changed considerably over the past 10 years, and we are now exploring how to integrate
In this explainer episode, we’ve asked James Duboff, Strategic Partnerships Director at Genomics Eng
Ethical considerations are essential in genomic medicine and clinical practice. In this episode, our
In this explainer episode, we’ve asked Professor Matt Brown, Chief Scientific Officer at Genomics En
In this explainer episode, we’ve asked Will Navaie, Head of Ethics Operations at Genomics England, t
In this explainer episode, we’ve asked Marie Nugent, Community Manager for the Diverse Data Initiati
In this explainer episode, we’ve asked Ellen Thomas, Interim Chief Medical Officer at Genomics Engla
Joey was diagnosed with DYRK1A syndrome at the age of 13, through the 100,000 Genomes Project. DYRK1
In this explainer episode, we’ve asked Clare Kennedy, Clinical Bioinformatician at Genomics England,
There are a range of outcomes from a genomic test. The results might provide a diagnosis, there may
In this explainer episode, we’ve asked Helen Brittain, Clinical Lead for Rare Disease Diagnostics at
29 February marks Rare Disease Day. This day is an opportunity for the rare community to come togeth
In this explainer episode, we’ve asked David Bick, Principal Clinician for the Newborn Genomes Progr
In January we saw experts from across the genomics ecosystem, including patients and those with an i
In this explainer episode, we’ve asked Ana Lisa Tavares, Clinical Lead for rare disease research at
